Health experts are urging government regulators to take action to protect the nation's youth by restricting the use of artificial tanning devices, which are linked to an increase in the risk of skin cancer, according to an article published online in the March 18, 2013 edition of Pediatrics, the journal of the American Academy of Pediatrics.
Indoor tanning has grown rapidly over the years with…Continue
Added by Peter Hofland, PhD on March 18, 2013 at 8:00am — No Comments
A new drug combination including an EGFR and COX-2 Inhibitors shows promise in reducing the risk for patients with advanced oral precancerous lesions to develop squamous cell carcinoma of the head and neck. The results of the study, which included preclinical and clinical analyses, were published in Clinical Cancer Research, a journal of the American Association for Cancer…Continue
Added by Peter Hofland, PhD on February 19, 2013 at 8:00pm — No Comments
New results from phase III trials exploring treatment options for patients with advanced renal cell carcinoma were released at the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna (September 28 - October 2, 2012). Renal cell carcinoma, also called kidney cancer or renal adenocarcinoma, is a type of kidney cancer that starts in the lining of the tubules in the kidney.
Prof Maria De Santis from Kaiser Franz Josef-Spital, Vienna, Chair of the ESMO 2012…Continue
Added by Peter Hofland, PhD on October 1, 2012 at 8:00pm — No Comments
Earlier this week the first patient has been dosed in a Phase Ib/IIa study of CRLX101 (formerly called IT-101, Cerulean Pharma Inc.), dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha, in combination with bevacizumab (Avastin®, Genentech/Roche) in metastatic renal cell carcinoma (mRCC) patients. Cerulean also announced the completion of enrollment of its randomized Phase II study in advanced non-small…Continue
Added by Peter Hofland, PhD on July 2, 2012 at 7:00pm — No Comments
HIV-infected patients are at increased risk for cancer as a result of both their impaired immune system and lifestyle factors, such as smoking, according to researchers at Kaiser Permanente.
The study, which appears in the current issue of Cancer Epidemiology, Biomarkers and Prevention, is among the first to directly compare the…
Added by Peter Hofland, PhD on November 22, 2011 at 11:00am — No Comments
Use of acetaminophen and nonaspirin nonsteroidal anti-inflammatory drugs (NSAID) was associated with a significantly increased risk for developing renal cell carcinoma, according to data presented at the 10th AACR International Conference on Frontiers in Cancer Prevention Research, held in Boston, Massachusetts (USA), Oct. 22-25, 2011.…Continue
Added by Peter Hofland, PhD on October 24, 2011 at 4:30pm — No Comments
Researchers confirmed an association between tanning bed use and an increased risk for three common skin cancers — basal cell carcinoma, squamous cell carcinoma and melanoma, according to results presented at the 10th AACR International Conference on Frontiers in Cancer Prevention Research, held in Boston, Massachusetts (USA), Oct. 22-25,…Continue
Added by Peter Hofland, PhD on October 24, 2011 at 4:30pm — No Comments
An antiparasitic agent used to treat African sleeping sickness (Human African trypanosomiasis or HAT)might someday be used to prevent nonmelanoma skin cancers. Researchers found that Eflornithine (DFMO, or α-difluoromethylornithine), still appeared to protect against nonmelanoma skin cancers years after people stopped taking the drug, according to a poster presented at the 10th AACR International Conference on…Continue
Added by Peter Hofland, PhD on October 23, 2011 at 4:30pm — No Comments
For the first time, scientists at Dana-Farber Cancer Institute and the Broad Institute have found strikingly high levels of a bacterium in colorectal cancers. The researchers believe that the bacterium may contribute to the disease and could potentially be a key to diagnosing, preventing, and treating it.
In a study published online in the…
Added by Peter Hofland, PhD on October 17, 2011 at 5:00pm — No Comments
Scientists at the University of Pittsburgh Cancer Institute have begun to uncover how the virus that causes most Merkel cell carcinoma (MCC) – a rare and aggressive skin cancer – operates, meaning that a rational chemotherapeutic target for this cancer could be developed in the near future.
Patrick Moore, M.D., M.P.H., an American Cancer Society…
Added by Peter Hofland, PhD on September 15, 2011 at 11:00am — No Comments
Added by Peter Hofland, PhD on June 20, 2011 at 10:00am — No Comments
Added by Peter Hofland, PhD on June 7, 2011 at 2:30am — No Comments
Added by Peter Hofland, PhD on May 19, 2011 at 3:30pm — No Comments
The U.S. Food & Drug Administration (FDA) has approved a Special Protocol Assessment (SPA) for a Phase III clinical trial of pegylated arginine deiminase (ADI-PEG 20, Polaris Group) in patients with advanced hepatocellular carcinoma (HCC).
ADI-PEG 20 is a novel protein therapeutic that has demonstrated anti-tumor activity and safety in Phase I & II clinical trials of patients with metastatic…
Added by Peter Hofland, PhD on March 31, 2011 at 5:00am — No Comments
Added by Peter Hofland, PhD on March 3, 2011 at 9:00am — No Comments
Although considerable work is underway in the development of new approaches to therapy for melanoma, an aggressive form of skin cancer that begins in skin cells called melanocytes, primary prevention continues to serve as the leading strategy. While not as common as other major types of skin cancer, including basal cell and squamous cell carcinoma, the average lifetime risk of developing skin melanoma is about 1%.…
Added by Peter Hofland, PhD on February 4, 2011 at 5:30am — No Comments
Aleisha Hunter, a 4-year old girl from Cambridge, Ontario (Canada), is thought to be the youngest breast cancer survivor in the world.
Today, the broad smile on her face and her abundant energy, so typical for a girl of her age, does not show the 15-month-long medical nightmare she endured that ultimately led medical staff in the North York General Hospital (Ontario, Canada) to a diagnosis of a rare form of breast cancer and a surgery for a radical…
Added by Peter Hofland, PhD on January 20, 2011 at 7:00am — No Comments
Research conducted in the Kanzius/Curley Lab at The University of Texas M.D. Anderson Cancer Center for the first time demonstrates that radiofrequency fields can treat pancreatic andenocarcinomas. The researchers found that noninvasive radiofrequency (RF) fields were effective in controlling relatively large pancreatic cancer cells without any…Continue
Added by Peter Hofland, PhD on January 13, 2011 at 3:00pm — No Comments
Analysis of human tissue samples in a Phase I human clinical trial with ALN-VSP (Alnylam Pharmaceuticals), for the first time demonstrated strong proof of RNAi in man. ALN-VSP, an RNAi therapeutic for the treatment of hepatocellular carcinoma and other solid tumors with liver involvement, contains two small interfering RNAs (siRNAs) formulated in a proprietary first generation lipid nanoparticle (LNP) formulation developed by…Continue
Added by Peter Hofland, PhD on January 13, 2011 at 5:30am — No Comments
Added by Peter Hofland, PhD on September 28, 2010 at 10:30am — No Comments